ConductScience.org, home

Gene · 135152

B3GAT2: beta-1,3-glucuronyltransferase 2

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. B3GAT2: beta-1,3-glucuronyltransferase 2. Genes, record 135152. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/135152

On this page

Gene

Symbol
B3GAT2
HGNC
Name
beta-1,3-glucuronyltransferase 2
HGNC
NCBI Gene ID
135152
NCBI Gene
HGNC ID
HGNC:922
HGNC
Ensembl
ENSG00000112309
NCBI Gene
Aliases
GLCATS, GlcAT-S
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9NPZ5Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 23231Ensembl, GeneID, HGNC

Source UniProt

Patents19

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4641201 A22025-10-29535Q9NPZ5Espacenet
JP 2025529142 A2025-09-04556Q9NPZ5Espacenet
US 12371689 B22025-07-29556Q9NPZ5Espacenet
JP 2025517969 A2025-06-12535Q9NPZ5Espacenet
WO 2025093745 A12025-05-0868Q9NPZ5Espacenet
JP 2025062604 A2025-04-148971Q9NPZ5Espacenet
JP 2025032204 A2025-03-1125036Q9NPZ5Espacenet
EP 4461818 A22024-11-1325036Q9NPZ5Espacenet
JP 2023058610 A2023-04-2525036Q9NPZ5Espacenet
US 11446398 B22022-09-208971Q9NPZ5Espacenet

1 to 10 of 19

See all 19 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants908

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleB3GAT2 papersNewest fiscal year
P30ES005022Rutgers Center for Environmental Exposure and Disease (CEED)82025
ZIABC005708Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers82025
P30CA077598Cancer Center Support Grant62025
P42ES013661Iowa Superfund Research Program: Airborne PCBs: Sources, Exposures, Toxicities, Remediation62025
P30CA015704Cancer Center Support Grant52025
P30ES005605Environmental Health Sciences Research Center52025
ZIABC005562Xenobiotic receptors52025
P01CA138338Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking32025
P30CA006973Regional Oncology Research Center32025
P30CA015083Mayo Clinic Comprehensive Cancer Center Support Grant32025

1 to 10 of 908Source NIH's project files

See all 908 nih grants

Papers1,850

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Hypericin and hyperforin from St. John's Wort are potent intestinal UGT inhibitors with distinct binding modes: mechanistic and quantitative prediction of clinical drug-drug interaction risk.Front Pharmacol202642787300PubTator, text miningPubMed
Coumarins at the Crossroads of Drug Development: Enzyme Modulation for Clinical Advances.Indian J Clin Biochem202642712839PubTator, text miningPubMed
Multilayered clearance concept: a membrane-resolved flux framework for drug metabolism.Biochem Pharmacol202642702242PubTator, text miningPubMed
The Dual Role of Human UDP-Glucuronosyltransferase-Mediated Metabolism in Tumor Drug Resistance: Mechanisms and Prospects.Int J Mol Sci202642589609PubTator, text miningPubMed
Testosterone and epitestosterone differentially regulate UDP-glucuronosyltransferases (UGT) activity.J Steroid Biochem Mol Biol202642303060PubTator, text miningPubMed
Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism.Front Pharmacol202642239518PubTator, text miningPubMed
Extracellular vesicles as xenobiotic-metabolizing enzyme carriers: a new paradigm for brain drug metabolism.Drug Metab Rev202642060154PubTator, text miningPubMed
An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents.Pediatr Blood Cancer202642057496PubTator, text miningPubMed
Genetic Variation in CYP2B6, UGT1A4 and Sulfotransferases Is Associated with Disease-Free Survival in South African Breast Cancer Patients Treated with Tamoxifen.J Pers Med202642042555PubTator, text miningPubMed
Systematic transcriptomic analysis of UDP-glucuronosyltransferases reveals UGT2B11 as a diagnostic and metabolic marker in hepatocellular carcinoma.BMC Cancer202642015107PubTator, text miningPubMed

1 to 10 of 1,850

See all 1,850 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/135152

GET https://conductscience.org/api/genes/v1/135152/patents